On February 27, 2025, Mihael Polymeropoulos, President and Chief Executive Officer of Vanda Pharmaceuticals Inc (VNDA, Financial), purchased 10,000 shares of the company. Following this transaction, the insider now owns a total of 2,351,730 shares. The details of this transaction can be found in the SEC Filing. Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company is involved in the research and development of innovative treatments for central nervous system disorders. The insider's recent purchase is part of a broader trend observed over the past year, where Mihael Polymeropoulos has acquired a total of 30,000 shares and sold 55,172 shares. In the same period, Vanda Pharmaceuticals Inc has seen a total of four insider buys and seven insider sells. On the day of the recent purchase, shares of Vanda Pharmaceuticals Inc were trading at $4.76, giving the stock a market cap of $274.669 million. The stock's GF Value is estimated at $5.29, resulting in a price-to-GF-Value ratio of 0.9, indicating that the stock is modestly undervalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also incorporates a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
